Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Royalty Pharma Plc Cl A
(NQ:
RPRX
)
29.13
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 29, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Royalty Pharma Plc Cl A
< Previous
1
2
3
4
5
6
Next >
Warren Buffett's Berkshire Takes Another Bite Of Apple, Boosts Energy Holdings, Cashes Out Of Verizon: What 13F Filing Reveals
August 16, 2022
Warren Buffett-owned Berkshire Hathaway, Inc.’s (NYSE: BRK-A) (NYSE: BRK-B) portfolio saw some noteworthy and a few other nominal changes in the second quarter, according to the company's 13F filing.
Via
Benzinga
Jim Cramer Shares His Takes On First Solar, Royalty Pharma And More
August 11, 2022
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Royalty Pharma PLC (NASDAQ: RPRX) is going higher. "Hold on to it."
Via
Benzinga
Expert Ratings for Royalty Pharma
August 08, 2022
Within the last quarter, Royalty Pharma (NASDAQ:RPRX) has observed the following analyst ratings:
Via
Benzinga
Royalty Pharma: Q2 Earnings Insights
August 04, 2022
Royalty Pharma (NASDAQ:RPRX) reported its Q2 earnings results on Thursday, August 4, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
The Daily Biotech Pulse: Much Awaited FDA Nod For Novavax's COVID-19 Shot, DSMB Suggests ContraFect To Stop Antimicrobial-Resistant Infection Study, CytomX Restructures
July 14, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Expert Ratings for Royalty Pharma
June 14, 2022
Royalty Pharma (NASDAQ:RPRX) has observed the following analyst ratings within the last quarter:
Via
Benzinga
Executives Sell Around $325M Of 3 Stocks
May 24, 2022
Gold futures traded higher this morning on Tuesday. Investors, meanwhile, focused on some notable insider trades.
Via
Benzinga
Theravance Biopharma, Innoviva Gain On Selling TRELEGY ELLIPTA Royalty Interests
July 13, 2022
Via
Benzinga
Warren Buffett Stocks: Royalty Pharma plc
July 08, 2022
As of March 31st, 2022, Buffett’s Berkshire Hathaway owned about 1.5 million shares of Royalty Pharma plc for a market value of $58.3 million. Let's analyze the healthcare company in greater detail.
Via
Talk Markets
This Analyst Thinks Blueprint Medicines' Non-Dilutive Funding 'Deflates M&A Speculation'
June 30, 2022
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 14, 2022
June 14, 2022
Upgrades
Via
Benzinga
Expert Ratings for Royalty Pharma
May 13, 2022
Analysts have provided the following ratings for Royalty Pharma (NASDAQ:RPRX) within the last quarter:
Via
Benzinga
Royalty Pharma: Q1 Earnings Insights
May 05, 2022
Royalty Pharma (NASDAQ:RPRX) reported its Q1 earnings results on Thursday, May 5, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Recap: Royalty Pharma Q1 Earnings
May 05, 2022
Royalty Pharma (NASDAQ:RPRX) reported its Q1 earnings results on Thursday, May 5, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Management of Technology Companies Continue Selling - Zillow (Z)
May 31, 2022
In a week where we saw most market indices rebound sharply, insiders scaled back their buying after three weeks of elevated buying. Buying declined by 64% in absolute dollar terms and 26% in terms of...
Via
Benzinga
Royalty Pharma Earnings Perspective: Return On Capital Employed
May 27, 2022
Pulled from Benzinga Pro data, Royalty Pharma (NASDAQ:RPRX) posted Q1 earnings of $128.08 million, an increase from Q4 of 138.64%. Sales dropped to $562.00 million, a 2.43% decrease between quarters.
Via
Benzinga
Warren Buffett Stocks: Berkshire Hathaway Goes On Offense In Stock Market, Adds More Apple
May 16, 2022
Buffett's Berkshire added to Apple and Chevron during the Q1 sell-off. More details to come.
Via
Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For May 13, 2022
May 13, 2022
Upgrades
Via
Benzinga
How To Attend Royalty Pharma Q1 2022 Earnings Conference Call
May 03, 2022
Royalty Pharma (NASDAQ:RPRX) will host a conference call at 08:00 AM ET on May 5, 2022, to discuss Q1 2022 earnings results. How to Attend Royalty Pharma (RPRX) Conference Call Follow this link to...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 14, 2022
April 14, 2022
Upgrades
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 6, 2022
April 06, 2022
Upgrades
Via
Benzinga
Expedia And 3 Other Stocks Insiders Are Selling
March 31, 2022
Although gold futures traded lower on Thursday, there were a few notable insider trades. When insiders sell shares, it indicates their concern in the company’s prospects or...
Via
Benzinga
Hopeful Golden Cross Forms On Royalty Pharma's Chart
March 01, 2022
If history is any guide, there may be good fortune ahead for shares of Royalty Pharma (NASDAQ:RPRX). A so-called "golden cross" has formed on its chart and, not surprisingly,...
Via
Benzinga
Looking Into Royalty Pharma's Return On Capital Employed
February 16, 2022
According to Benzinga Pro, during Q4, Royalty Pharma (NASDAQ:RPRX) earned $53.67 million, a 75.8% increase from the preceding quarter. Royalty Pharma's sales decreased to $576.00 million, a 1.67%...
Via
Benzinga
The Daily Biotech Pulse: Larimar Plunges On Extension Of Clinical Hold, ImmunityBio Gains On Positive Data, Adcom Test Awaits Avenue Therapeutics
February 15, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus ImmunityBio Says Cancer Combo Therapy Produces Positive Results In Late-Stage...
Via
Benzinga
ProKidney Turns To Palihapitiya-Backed SPAC To Go Public In $2.6B Deal
January 18, 2022
ProKidney LP agreed to become a publicly-traded company via a business combination with Chamath Palihapitiya-backed special purpose acquisition company Social Capital...
Via
Benzinga
DNAC Stock Alert: Chamath Palihapitiya’s SPAC Preps for ProKidney Merger
January 18, 2022
Investors are excited to hear that dealmaker Chamath Palihapitiya is proceeding with a new SPAC deal involving ProKidney.
Via
InvestorPlace
Earnings Scheduled For February 15, 2022
February 15, 2022
Companies Reporting Before The Bell • FirstService (NASDAQ:FSV) is estimated to report quarterly earnings at $1.31 per share on revenue of $1.07 billion.
Via
Benzinga
2 Chamath Palihapitiya SPAC Deals Rumored: Will He Land The Year's First Deal Once Again?
January 09, 2022
The 2022 year has started quietly for SPACs, with no deals announced in the first five trading days of the year. Although two new SPAC rumors have popped up since the market...
Via
Benzinga
Jim Cramer Shares His Thoughts On Canadian Pacific Railway, Royalty Pharma And More
December 10, 2021
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Canadian Pacific Railway Limited (NYSE:
Via
Benzinga
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.